Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Folia Medica Indonesiana
Budi Utomo
Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Longer Lag Time in Early-Stage Retinoblastoma Anindya Citra; Budi Utomo; Hendrian Dwikoloso Soebagjo
Folia Medica Indonesiana Vol. 58 No. 2 (2022): June
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (720.645 KB) | DOI: 10.20473/fmi.v58i2.24975

Abstract

Highlights: Patients with IRSS I stage have the longest lag time than IVB stage. Lag time is no significant with stage retinoblastoma.   Abstract: Retinoblastoma is a rare neoplasm disease that occurs in children, generally under the age of two. Retinoblastoma is more prevalent in developing countries and is often associated with a late diagnosis. Such delays can lead to a poor prognosis. The time from the appearance of symptoms of retinoblastoma (onset) to the time of diagnosis is called lag time. Early diagnosis of retinoblastoma by paying attention to factors such as age, clinical symptoms, and laterality can help improve retinoblastoma survival rates, especially in developing countries. The purpose of this study was to analyze the relationship between the lag time to the stage of retinoblastoma patients at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. This study was a retrospective analytical observational study using secondary data from retinoblastoma patients at the Ophthalmology Outpatient Unit at Dr. Soetomo General Academic Hospital, Surabaya, from January 2014 to December 2018. The data were analyzed using Kendall's tau-C test. No significant correlation was found between lag time and stage (p = 0.339). Patients with International Retinoblastoma Staging System (IRSS) I stage had the longest lag time (on average 28 months), and patients with stage IVB had the shortest lag time (on average four months). There was no correlation between lag time and retinoblastoma stage. However, there was a trend of patients with early stages delaying hospital visits, while patients with advanced stages in earlier to the hospital.
Optimal Dose of Vitamin D For Covid-19 Treatment Dita Mega Utami; Muhammad Abdurrahman Rasyid Ash-Siddiq; Desi Rianti Rahmahani; Muhammad Iqbal Mubarok; Muhammad Zulkifly Tasman; Jeremy Nicolas Sibarani; Habibah Teniya Ariq Fauziyah; Budi Utomo; Shifa Fauziyah
Folia Medica Indonesiana Vol. 58 No. 4 (2022): December
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (838.38 KB) | DOI: 10.20473/fmi.v58i4.36474

Abstract

Highlights: Vitamin D supplementations in different doses yield different outcomes. Multi-day vitamin D administration of 1000-6000 IU in patients with COVID-19 has more positive impacts than a single high dose of vitamin D. Patient morbidity, length of hospitalization, and patient mortality improved with multi-day vitamin D administration.   Abstract: This meta-analysis aimed to determine whether there is any optimal dose of vitamin D for morbidity, length of hospitalization, and mortality in patients with COVID-19. We conducted a comprehensive search in three online databases for eligible studies until February 28, 2022. Odds ratio (OR) and standardized mean difference (SMD) were applied as summary statistics of primary outcomes. The study quality of the literatures collected was assesed using the Cochrane risk of bias tool version 2 (RoB 2). Eight randomized clinical trials (RCT) were included in the study. In our analysis, we found that there was no significant difference in morbidity when vitamin D was administered to COVID-19 patients [OR=0.50 (95% CI=0.13-1.96); SMD=-0.14 (95% CI=-0.55-0.28)]. Duration of hospitalization [SMD=-0.12 (95% CI=-0.39-0.15)] and mortality [OR 0.47 (95% CI=0.19-1.17)] of COVID-19 patients in five studies also showed no significant difference compared to patients who do not take vitamin D. However, when we analyzed two other studies, we found that in patients who did not take vitamin D, mortality was lower [SMD=0.43 (95% CI=0.29, 0.58)]. Compared to a single high dose of vitamin D, the multi-day vitamin D administration of 1000-6000 IU in patients with COVID-19 resulted in improved patient morbidity, length of hospitalization, and patient mortality.
Co-Authors Anindya Citra Desi Rianti Rahmahani Dita Mega Utami Habibah Teniya Ariq Fauziyah Jeremy Nicolas Sibarani Muhammad Abdurrahman Rasyid Ash-Siddiq Muhammad Iqbal Mubarok Muhammad Zulkifly Tasman Shifa Fauziyah Soebagjo, Hendrian Dwikoloso